SecBot SecBot
SECBOTREPLAY Home › Report › SANA

SANA · Sana Biotechnology announced 14-month data from a first-in-human study…

Sana Biotechnology, Inc · PRESS-RELEASE filed Mar 13, 2026 at 09:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 13, 2026 at 09:00 ET

Sana Biotechnology announced 14-month data from a first-in-human study showing that its hypoimmune (HIP)-modified islet cells (UP421) transplanted without immunosuppression survived long-term, evaded immune detection, and continued to produce insulin in a Type 1 Diabetes patient. The results support the potential for a functional cure and validate the HIP platform, with Sana planning to file an IND for its stem cell-derived therapy SC451 and initiate a Phase 1 trial this year.

  • 14-month follow-up data show sustained survival and function of HIP-modified islet cells without immunosuppression in a Type 1 Diabetes patient.
  • C-peptide levels, a biomarker of insulin production, were maintained at month 14 and increased during meal tests, indicating functional insulin secretion.
  • No safety issues were reported; cells evaded both allogeneic and autoimmune immune responses.
  • Improved glycemic control between months 12–14 correlated with enhanced beta cell function, suggesting dose-dependent potential.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access